Relationship between Weight Change Patterns and Health Satisfaction in the CANadian Canagliflozin Registry (CanCARE) Study
Authors: WOO VINCENT C. , BAJAJ HARPREET S. , CLEMENT MAUREEN A. , CAMACHO FERNANDO , TRAINA SHANA , GEORGIJEV NATASHA , ROSE JENNIFER B. , SORABJI DELNA , BELL ALAN D. 
Published: June 2018

Patient health satisfaction is associated with positive health behaviors and is considered important for optimal management of type 2 diabetes mellitus (T2DM). In previously reported randomized clinical trials (RCTs) of canagliflozin (CANA), CANA reduced HbA1c, body weight, and blood pressure. CanCARE is a prospective, observational, 12-month registry for people living with T2DM newly initiated on CANA. The Current Health Satisfaction Questionnaire (CHES-Q) was administered in this study at baseline (BL) and repeated at 3, 6 and 12 months. We report the pre-specified analyses investigating the relationship between current health satisfaction agreement on CHES-Q with weight change patterns defined as: Pattern 1 (loss from BL to month 3 and loss from month 3 to 12); Pattern 2 (loss from BL to month 3 and gain from month 3 to 12); Pattern 3 (gain from BL to month 3 and loss from month 3 to 12); and Pattern 4 (gain from BL to month 12).

At month 12, 75.4% of subjects (389/516) completed the CHES-Q, of which 318 patients, with available data, had a mean weight loss of 3.2 kg (7.1 lbs). Proportion of subjects with weight loss patterns were: 55.5%, 25.5%, 13.2% and 4.8% for patterns 1, 2, 3, and 4, respectively. Satisfaction agreement with current health increased from 46.5% to 67.9%, 52.5% to 63.9%, 40.0% to 44.7%, and 20.0% to 26.7% within weight loss patterns 1, 2, 3, and 4, respectively. Based on 290 subjects with available data, 64.2%, 65.3% and 60.5% in patterns 1, 2, and 3 reported satisfaction agreement maintenance or improvement with current health between baseline and month 12; with relatively less maintenance or improvement (46.7%) among those with Pattern 4 (weight gain).

This analysis shows that real world use of CANA offers weight loss consistent with that seen in CANA RCTs and suggests a direct correlation between weight change patterns and health satisfaction for people living with T2DM.

Disclosure

V.C. Woo: Advisory Panel; Self; Janssen Pharmaceuticals, Inc., AstraZeneca, Novo Nordisk Inc., Sanofi, Boehringer Ingelheim Pharmaceuticals, Inc., Merck & Co., Inc. H.S. Bajaj: Speaker's Bureau; Self; Abbott. Advisory Panel; Self; Amgen Inc.. Speaker's Bureau; Self; Amgen Inc.. Advisory Panel; Self; AstraZeneca. Consultant; Self; AstraZeneca. Research Support; Self; AstraZeneca. Speaker's Bureau; Self; AstraZeneca, Bayer AG. Advisory Panel; Self; Boehringer Ingelheim GmbH. Research Support; Self; Boehringer Ingelheim GmbH. Speaker's Bureau; Self; Boehringer Ingelheim GmbH. Advisory Panel; Self; Eli Lilly and Company. Research Support; Self; Eli Lilly and Company. Speaker's Bureau; Self; Eli Lilly and Company. Advisory Panel; Self; Janssen Pharmaceuticals, Inc.. Research Support; Self; Janssen Pharmaceuticals, Inc.. Speaker's Bureau; Self; Janssen Pharmaceuticals, Inc., Medtronic. Advisory Panel; Self; Merck & Co., Inc.. Research Support; Self; Merck & Co., Inc.. Speaker's Bureau; Self; Merck & Co., Inc., Mylan. Advisory Panel; Self; Novo Nordisk Inc.. Research Support; Self; Novo Nordisk Inc.. Speaker's Bureau; Self; Novo Nordisk Inc.. Advisory Panel; Self; Sanofi. Research Support; Self; Sanofi. Speaker's Bureau; Self; Sanofi. Advisory Panel; Self; Valeant Pharmaceuticals International, Inc.. Research Support; Self; Valeant Pharmaceuticals International, Inc.. Speaker's Bureau; Self; Valeant Pharmaceuticals International, Inc. M.A. Clement: Speaker's Bureau; Self; Janssen Pharmaceuticals, Inc., AstraZeneca, Novo Nordisk Inc., Sanofi-Aventis, Eli Lilly and Company. F. Camacho: Consultant; Self; Janssen Inc. S. Traina: Employee; Self; Janssen Global Services, LLC. N. Georgijev: Employee; Self; Janssen Scientific Affairs, LLC. J.B. Rose: Employee; Self; Janssen Pharmaceuticals, Inc. D. Sorabji: Employee; Self; Janssen Pharmaceuticals, Inc. A.D. Bell: Advisory Panel; Self; AstraZeneca, Janssen Pharmaceuticals, Inc., Bayer AG, Eli Lilly and Company, Novo Nordisk Inc.. Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Servier.